Fraunhofer Institute for Cell Therapy and Immunology IZITargeted inhibition of periodontitis pathogens
Periodontitis is widespread and can have serious consequences for overall health. Researchers at the Department of Drug Design and Target Validation of the Fraunhofer Institute for Cell Therapy and Immunology IZI have identified a substance that selectively blocks harmful pathogens such as Porphyromonas gingivalis without affecting other bacteria. Thereby, the natural balance of the oral microbiome is preserved. A toothpaste containing this substance is now available on the market.
The basis for this technology originated from an EU-funded project involving numerous international partners. The spin-off company Periotrap Pharmaceuticals GmbH was founded in Halle in 2018 with the aim of developing innovative oral care products. PerioTrap created its microbiome-friendly toothpaste in close collaboration with Fraunhofer IZI and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS. The Fraunhofer IZI team conducted biochemical analyses and structural biology studies to support product development.